This article has been updated to include information from a conference call and Luminex's closing stock price.
 
NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared Luminex’s molecular diagnostic panel for a dozen viruses that account for over 85 percent of respiratory viral infections, including various influenza strains, the company said today.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.